Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05386043 · ClinicalTrials.gov registry record
Registering Genomics and Imaging of Tumors (ReGIT)
A clinical trial of Glioma, sponsored by Indiana University.
- Recruiting
- Registry status
- 20
- Enrollment target
- 1
- Study location
NCT05386043 is a study of Glioma that is actively recruiting participants, run by Indiana University. The registered enrollment target is 20 participants, below the 210-participant average among 87 other Glioma trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05386043, a study of Glioma, is actively recruiting participants, sponsored by Indiana University.
- RECRUITING
- Registry status
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is investigating how brain tumors might mutate over time, and whether new brain imaging tools like MRI and PET can predict these mutations.
Conditions Studied
Interventions
- DRUG FET F-18
- DRUG O-15 Radioisotope
- PROCEDURE CT scan
- PROCEDURE MRI with gadolinium-based contrast
- PROCEDURE Biopsy Collection
Study Locations (1)
Indiana
- Indiana University School of Medicine - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2023-07-18 |
| Est. Completion | 2032-07-17 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05386043
The ClinicalTrials.gov registry entry for NCT05386043 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 210-participant average among 87 other Glioma trials with a reported enrollment target (90% lower). The listed sponsor is Indiana University, which has 890 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Glioma appearing as the primary indexed condition, and to 5 interventions - of which FET F-18 is the first listed.
NCT05386043 reports 1 study location spanning 1 distinct geographic area - top geographies include Indiana.
Frequently Asked Questions
What is clinical trial NCT05386043 about?
NCT05386043 is a clinical study titled "Registering Genomics and Imaging of Tumors (ReGIT)". This study is investigating how brain tumors might mutate over time, and whether new brain imaging tools like MRI and PET can predict these mutations.
What is the current status of trial NCT05386043?
This trial is currently recruiting. The enrollment target is 20 participants. The study started on 2023-07-18. Estimated completion is 2032-07-17.
What conditions does trial NCT05386043 study?
This clinical trial studies the following conditions: Glioma.
What interventions are being tested in trial NCT05386043?
The interventions under investigation include: FET F-18 (DRUG), O-15 Radioisotope (DRUG), CT scan (PROCEDURE), MRI with gadolinium-based contrast (PROCEDURE), Biopsy Collection (PROCEDURE).
Who is sponsoring clinical trial NCT05386043?
This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05386043 being conducted?
This trial has 1 study location across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma
RECRUITING · Phase 2
-
Tumor Treating Fields for the Treatment of Brainstem Gliomas
RECRUITING · NA
-
Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies
RECRUITING · Phase 4
-
Cognitive Changes of IDH-mutant and IDH-wildtype Glioma Patients After Chemoradiotherapy With Radiation Dose to the Resting State Networks
RECRUITING
-
Zr-89 Crefmirlimab Berdoxam and Immuno-Positron Emission Tomography for the Imaging of Patients With Resectable Brain Tumors
RECRUITING · Phase 1
-
Sequential Treatments or Combinations Including Dasatinib, Quercetin, Fisetin and/or Temozolomide for the Treatment of Previously Treated Glioma With Residual Disease
RECRUITING · Early Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.